Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Impact · against what's priced in

Zevra Therapeutics shows strong operational momentum with a 78% year-over-year revenue increase and a strengthened balance sheet. The combination of debt repayment and a $50 million portfolio sale significantly reduces financial risk while confirming the commercial viability of MIPLYFFA.

ZVRA+0.70

No priced-in read yet

In context

Q1 2026 net revenue grew 78% to $36.2 million, and the company eliminated its term loan debt while securing $236.8 million in cash following the $50 million sale of its SDX portfolio.

Read from the article alone

• earnings▲15%
• revenue growth▲3%
• pharmaceuticals
• biotech
• ZVRA
• cash position
• divestiture
• fda approval